Abivax SA ADR (ABVX)
Abivax: Obefazimod Goes The Distance And So Does My Buy Rating
Abivax (ABVX) maintains a Buy rating, supported by robust Phase 3 maintenance data for obefazimod in ulcerative colitis. ABVX demonstrated clinical remission rates of 50.8%–51.3% at week 44, with strong secondary endpoints and a favorable safety profile. A recent $920M capital raise funds operations into Q4 2029, enabling standalone commercialization and strengthening strategic positioning.
Should You Buy Abivax SA Sponsored ADR (ABVX) After Golden Cross?
After reaching an important support level, Abivax SA Sponsored ADR (ABVX) could be a good stock pick from a technical perspective. ABVX recently experienced a "golden cross" event, which saw its 50-day simple moving average breaking out above its 200-day simple moving average.
Abivax $920 million cash haul lets it prepare for solo U.S. launch instead of relying on a buyer, CEO tells CNBC
Abivax's latest funding round allows the biotech to move toward a U.S. launch of its bowel disease drug without backing from Big Pharma, its CEO told CNBC on Friday. The French biotech has been under intense scrutiny as an acquisition target by a larger peer.
Abivax: Wall Street Catches Up to the Data
Shares of Abivax NASDAQ: ABVX were up more than 40% in the month ending July 6, after the company announced positive results from its late-stage (Phase 3) trial of its lead candidate, Obefazimod, which is being designed as a long-term maintenance treatment for ulcerative colitis (UC). The rally pushed ABVX nearly to its all-time high of $146.41, set in December 2025.
Abivax shares jump as updated trial data eases safety concerns
Abivax SA (NASDAQ:ABVX, EPA:ABVX, FRA:2X10, FRA:2X1) shares surged more than 40% on Tuesday after the French biotech released updated safety data from its late-stage ulcerative colitis program for its investigational drug obefazimod, easing earlier market concerns around reported cancer cases in the study. The company said the additional analysis showed that observed malignancy rates across its Phase 2 and Phase 3 program were consistent with background rates typically seen in patients with ulcerative colitis.
ABIVAX Société Anonyme (ABVX) Discusses ABTECT Maintenance Part 2 Results and Updated Obefazimod Safety and Efficacy Data in Ulcerative Colitis Transcript
ABIVAX Société Anonyme (ABVX) Discusses ABTECT Maintenance Part 2 Results and Updated Obefazimod Safety and Efficacy Data in Ulcerative Colitis Transcript
Abivax inflammatory bowel drug shows benefit in relapsed and non-responding patients
Abivax said on Monday its experimental ulcerative colitis drug helped harder-to-treat groups of patients achieve remission, with the biotech calling the results a boost to the safety profile of its late-stage program.
Abivax SA Sponsored ADR (ABVX) Loses 41.4% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
The heavy selling pressure might have exhausted for Abivax SA Sponsored ADR (ABVX) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
ABIVAX Société Anonyme (ABVX) Discusses Positive Phase III ABTECT Trial Results for Obefazimod in Ulcerative Colitis Transcript
ABIVAX Société Anonyme (ABVX) Discusses Positive Phase III ABTECT Trial Results for Obefazimod in Ulcerative Colitis Transcript
Abivax Shares Plunge After Company Reports Adverse Events in Key Drug Trial
The biotech said some patients developed cancer in a late-stage clinical trial for the bowel-disease drug that were unrelated to the treatment.
Abivax stock crashes as safety fears overshadow bowel disease drug trial win
Abivax shares fell 31% even after the French biotech reported strong late-stage data for obefazimod, its experimental treatment for ulcerative colitis. The once-daily oral therapy met the main goal and all key secondary endpoints in a Phase 3 maintenance study, strengthening the case for a potential new option in a market still led by injectable biologics and other advanced treatments.
Biotech takeover target Abivax sinks over 30% after bowel disease drug trial update
Biotech takeover target Abivax sinks over 30% after bowel disease drug trial update
